|12 Months Ended|
Dec. 31, 2019
|Major components of tax expense (income) [abstract]|
NOTE 9 - INCOME TAX
The Company and its subsidiary are taxed under Israel tax laws:
The corporate tax rates applicable to 2019, 2018 and 2017 are 23%, 23% and 24%, respectively.
The Company and its subsidiary have tax assessments that are considered to be final through tax year 2014.
As of December 31, 2019, CollPlant Biotechnologies Ltd. and CollPlant Ltd had approximately $4,506, and $50,309, respectively, of net carry forward tax losses which are available to reduce future taxable income with no limited period of use.
Realization of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporary differences and carry forward losses are expected to be available to reduce taxable income. As the achievement of required future taxable income is not likely, the Company recorded a full valuation allowance.
The primary difference between the statutory tax rate of the Company and the effective rate results virtually from the changes in valuation allowance in respect of carry forward tax losses and research and development expenses due to the uncertainty of the realization of such tax benefits.
As of December 31, 2019 and 2018, the Company does not have a provision for uncertain tax positions.
The entire disclosure for income taxes.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef